Search results for " Surgery."

showing 10 items of 3972 documents

Invasive candida infections in neonates after major surgery: Current evidence and new directions

2021

Infections represent a serious health problem in neonates. Invasive Candida infections (ICIs) are still a leading cause of mortality and morbidity in neonatal intensive care units (NICUs). Infants hospitalized in NICUs are at high risk of ICIs, because of several risk factors: broad spectrum antibiotic treatments, central catheters and other invasive devices, fungal colonization, and impaired immune responses. In this review we summarize 19 published studies which provide the prevalence of previous surgery in neonates with invasive Candida infections. We also provide an overview of risk factors for ICIs after major surgery, fungal colonization, and innate defense mechanisms against fungi, a…

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtymedicine.drug_classInvasive Candida infections030106 microbiologylcsh:MedicineInvasive Candida infectionCandida infections03 medical and health sciencesBroad spectrumNeonatal surgeryinvasive <i>Candida</i> infections0302 clinical medicineInvasive fungal infectionInvasive fungal infectionsIntensive careEpidemiologyFungal colonizationImmunology and AllergyMedicineAntifungal prophylaxi030212 general & internal medicineMolecular BiologyNewbornsGeneral Immunology and Microbiologybusiness.industrylcsh:RImpaired immune responsesNewbornSurgeryNeonatal surgeryInfectious DiseasesSettore MED/20SurgeryAntifungal prophylaxisAntifungal prophylaxis; Invasive Candida infections; Invasive fungal infections; Neonatal surgery; Newborns; Surgerybusiness
researchProduct

Fast-Growing Alveolar Echinococcosis Following Lung Transplantation

2020

International audience; Alveolar echinococcosis is a rare but life-threatening infection caused by the parasiteEchinococcus multilocularis. Its natural history is characterized by a slow parasitic growth over several years. Increased incidence and shorter development delay have been reported in immune-compromised patients. We report the reactivation of aborted lesions within 12 months of lung transplantation leading to a fast-growing aggressive hepatic lesion. Timely identification of alveolar echninococcosis allowed prompt albendazole treatment and radical surgery leading to a favorable outcome 42 months after transplantation. However, close clinical, serological and radiological monitorin…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.medical_treatment030231 tropical medicinelcsh:MedicineCase ReportEchinococcus multilocularisliverAlbendazole03 medical and health sciences0302 clinical medicinemedicinelung transplantationImmunology and AllergyLung transplantationRadical surgeryMolecular Biology<i>Echinococcus multilocularis</i>immunosuppressionGeneral Immunology and Microbiologybiologybusiness.industryIncidence (epidemiology)lcsh:RImmunosuppression030108 mycology & parasitologybiology.organism_classification3. Good healthSurgeryNatural historyTransplantationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyparasiteEchinococcus multilocularisbusinessmedicine.drug
researchProduct

Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing : a split-mouth randomised clinical trial

2018

Background Since the discovery of adult mesenchymal stem cells extensive research has been conducted to determine their mechanisms of differentiation and effectiveness in cell therapy and regenerative medicine. Material and Methods To assess the efficacy of autologous dental pulp mesenchymal stem cells delivered in a collagen matrix for post-extraction socket healing, a single-centre, double-blind, randomised, split-mouth, controlled clinical trial was performed. Both impacted mandibular third molars were extracted from 32 patients. Dental pulp was collected and dissociated; the resulting cell suspension, obtained by centrifugation, was incorporated into a resorbable collagen matrix and imp…

0301 basic medicineMolarAdultMaleAdolescentDentistryBone healingMesenchymal Stem Cell TransplantationBone resorptionMandibular second molar03 medical and health sciencesYoung AdultDouble-Blind MethodHounsfield scaleMedicineHumansTooth SocketAutograftsGeneral DentistryDental PulpPostoperative CareWound Healingbusiness.industryResearchMesenchymal stem cellInterdental consonant:CIENCIAS MÉDICAS [UNESCO]030104 developmental biologyOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryFemaleMolar ThirdOral SurgeryWound healingbusiness
researchProduct

Hemodynamic variations and anxiety during the surgical extraction of impacted lower third molars

2019

Background The surgical removal of an impacted third molar can cause patient anxiety. Such anxiety and the use of vasoconstrictor drugs and local anesthetics in turn can induce hemodynamic variations during the operation. A study is made of the variations in hemodynamic parameters (systolic and diastolic blood pressure and heart rate) and their correlation to patient gender and anxiety during surgical removal of an impacted lower third molar. Material and methods A prospective study was carried out in the Oral Surgery Unit of a university clinic, with the inclusion of 125 patients (mean age 24.9 years). Anesthesia was administered in the form of 4% articaine and adrenalin 1:200,000 for surg…

0301 basic medicineMolarbusiness.industryResearchHemodynamics:CIENCIAS MÉDICAS [UNESCO]Articaine03 medical and health sciences030104 developmental biology0302 clinical medicineBlood pressureAnesthesiaStatistical significanceUNESCO::CIENCIAS MÉDICASHeart ratemedicineAnxietymedicine.symptomOral SurgeryProspective cohort studybusinessGeneral Dentistry030217 neurology & neurosurgerymedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Cheek-splitting technique for marginal mandibulectomy: A novel approach

2019

When performing marginal mandibulectomy, ensuring complete tumor removal and preventing postoperative iatrogenic mandibular fracture are essential. Pathological fracture can result due to stress concentration at the site requiring acute angle resection. To perform marginal mandibulectomy without making acute angles in patients with a lesion in the molar or more posterior region, a submandibular or transbuccal approach is necessary. Compared to the submandibular approach, the transbuccal approach is considered useful as it reduces operative time and prevents injury to the facial and mental nerves. Additionally, this approach does not leave a scar in the surgical field, which is beneficial in…

0301 basic medicineMolarmedicine.medical_specialtyMandibular fracturemedicine.medical_treatmentCase Report03 medical and health sciences0302 clinical medicinestomatognathic systemMedicineGeneral Dentistrybusiness.industryGingival CarcinomaNeck dissectionCheek:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgerystomatognathic diseases030104 developmental biologymedicine.anatomical_structureMandibulectomyUNESCO::CIENCIAS MÉDICASOperative timeTumor removalOral Surgerybusiness030217 neurology & neurosurgeryJournal of Clinical and Experimental Dentistry
researchProduct

The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution

2020

The immune system can recognize and attack cancer cells, especially those with a high load of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and to neoantigen-inducing translational frameshifts. Here, we develop a tool to quantify frameshift mutations in MSI colorectal and endometrial cancer. Our results show that frameshift mutation frequency is negatively correlated to the predicted immunogenicity of the resulting peptides, suggesting counterselection of cell clones with highly immunogenic frameshift peptid…

0301 basic medicineMutation rateGeneral Physics and Astronomymedicine.disease_causeCOLORECTAL-CANCER0302 clinical medicineINDEL MutationMutation RateimmunologiaHLA AntigensNeoplasmsFrameshift Mutationlcsh:ScienceImmunologic SurveillanceGeneticsMutationMultidisciplinaryMISMATCH REPAIR DEFICIENCYQPEPTIDES3. Good healthkohdunrungon syöpäsyöpäsolutimmuunivaste030220 oncology & carcinogenesisTumour immunologyMicrosatellite InstabilityDNA mismatch repairINDEL MutationEXPRESSIONcongenital hereditary and neonatal diseases and abnormalitieskasvaimetDATABASESciencegastrointestinal cancerINSTABILITY3122 CancerssuolistosyövätBiologycomplex mixturesArticleGeneral Biochemistry Genetics and Molecular BiologyFrameshift mutationGastrointestinal cancer03 medical and health sciencesAntigens NeoplasmCOLONmedicineHumansCELLSelection GeneticIndelSIGNATUREStumour immunologyMicrosatellite instabilityGeneral ChemistryDNAmedicine.disease3126 Surgery anesthesiology intensive care radiologydigestive system diseases030104 developmental biologyImmunoeditinglcsh:Qmutaatiotbeta 2-MicroglobulinMicrosatellite Repeats
researchProduct

ASO Author Reflections: How Long will We Perform Lymphadenectomy in Endometrial Cancer Patients?

2022

Abstract Objectives To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results The study incl…

0301 basic medicineN.A.medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeMEDLINEArticleEndometrial CancerDisease-Free Survival03 medical and health sciences0302 clinical medicineLymphadenectomy Endometrial CancerSurgical oncologyAdjuvant therapymedicineHumansStage IIICNeoplasm InvasivenessProgression-free survivalLymph nodeAgedNeoplasm StagingRetrospective Studiesbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyLymphadenectomymedicine.diseaseEndometrial Neoplasms030104 developmental biologymedicine.anatomical_structureTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIASentinel nodeOncology030220 oncology & carcinogenesisLymphatic MetastasisDisease ProgressionLymph Node ExcisionFemaleSurgeryLymphadenectomySentinel Lymph NodebusinessAlgorithmChemoradiotherapyAlgorithmsAnnals of Surgical Oncology
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

2019

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

0301 basic medicineOncologyPosition statementCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineBreast CancermedicineAdjuvant therapyHumansRadical surgeryskin and connective tissue diseasesNeoadjuvant therapyEarly breast cancerChemotherapybusiness.industrymedicine.diseaseNeoadjuvant Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisHormonal therapyFemalebusinessThe Oncologist
researchProduct

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

2017

Background: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology. Methods: Retrospective analysis was carried out in a subset of 31 patients with squamous histology enrolled in the study between September 2007 and September 2015. All o…

0301 basic medicineOncologyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyBevacizumabmedicine.medical_treatmentSquamous-NSCLC (sqNSCLC)03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalRadical surgeryEtoposideEtoposideChemotherapybusiness.industryMetronomic chemotherapyCancermedicine.diseaseMetronomic ChemotherapyBevacizumabRegimen030104 developmental biology030220 oncology & carcinogenesisOriginal ArticleCisplatinbusinessBevacizumab; Cisplatin; Etoposide; Metronomic chemotherapy; Squamous-NSCLC (sqNSCLC); Pulmonary and Respiratory Medicinemedicine.drug
researchProduct